title: Fibrinogen and plasminogen modifications during oral estradiol replacement therapy.
abstract: OBJECTIVE
  To assess the effects of oral E2 replacement therapy on various hemostatic parameters and cardiovascular risk factors in healthy, postmenopausal women.
  
  
  METHODS
  A double-blind, randomized, prospective study comparing the effect of a placebo and of oral micronized E2 (2 mg daily) during a 6-month period. Evaluations were performed before treatment and after 3 and 6 months.
  
  
  METHODS
  Departments of Gynecology, Hemostasis, and Nutrition, Hôtel-Dieu, Paris, France.
  
  
  METHODS
  Thirty-six healthy women with natural or surgical menopause.
  
  
  RESULTS
  Compared with placebo, oral E2 replacement therapy resulted in a significant decrease in fibrinogen and apo B and a significant increase in plasminogen.
  
  
  CONCLUSIONS
  Besides the effects on lipoproteins, oral estrogen replacement therapy modifies parameters involved in coagulation and fibrinolysis.
authors.affiliation: Department of Hemostasis, Hôtel-Dieu, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Conard
authors.forename: A
authors.initials: A
authors.lastname: Gompel
authors.forename: C
authors.initials: C
authors.lastname: Pelissier
authors.forename: C
authors.initials: C
authors.lastname: Mirabel
authors.forename: A
authors.initials: A
authors.lastname: Basdevant
mesh_terms: D000284:Administration, Oral; D000990:Antithrombin III / Q000032:analysis; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D008055:Lipids / Q000097:blood; D017270:Lipoprotein(a) / Q000097:blood; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis*; D011446:Prospective Studies
chemical_list: D008055:Lipids; D017270:Lipoprotein(a); D004958:Estradiol; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen